DASH Trial
Start date:June 2019
Why?
Medications to ‘thin’ the blood can have an unwanted effect on strokes caused by bleeding in the brain. Controlling bleeding is crucial in the first few hours after stroke but there is still uncertainty over the best course of treatment.
What?
DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.
Research Team
Allan MacRaild
Stroke Lead Research Nurse
Seona Burgess
Senior Stroke Research Nurse
Pat Taylor
Senior Stroke Research Nurse
Rachel O'Brien
Lead Research Nurse
Julia Grahamslaw
Lead Research Nurse
Fiona McCurrach
Senior Research Nurse
More EMERGE Trials
TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.
TARGET-CTCA Trial
ATTEST2 Trial
Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)